Transactions
2
Insider / Immunovant, Inc.
Roivant Sciences Ltd.
Director at Immunovant, Inc.
- Company
- Immunovant, Inc.
- First filing on record
- December 12, 2025
- Latest trade on record
- October 1, 2026
- SEC filings
- EDGAR ↗
Roivant Sciences Ltd., Director at Immunovant, Inc., has disclosed 2 transactions in ROIV, IMVT since December 12, 2025: 1 purchase (1 open-market buy) and 1 sale, worth about $394.8M at the reported prices. The latest was filed October 5, 2026, 4 days after the trade.
Open-market buys
1
Sales
1
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)
In the last 12 months Roivant Sciences Ltd. made 1 purchase worth $350M and 1 sale worth $45M. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Roivant Sciences Ltd. has traded 2 stocks on record; the largest by dollars is IMVT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| D | Sale back to the company | 1 | 8,967,383 | $44.8M |
| P | Open-market purchase | 1 | 16,666,666 | $350.0M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 1 · $44.8M |
| 2025 | 1 | 1 · $350.0M | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ROIV | Sell D | October 1, 2026 | October 5, 2026 | 4d | 8,967,383 | $5 | $44.8M | Form 4 ↗ | ||
| IMVT | Buy P | December 12, 2025 | December 12, 2025 | 0d | 16,666,666 | $21 | $350.0M | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 5, 2026 | Form 4 | 0001140361-26-038692 | 1 | published | EDGAR ↗ |
| December 12, 2025 | Form 4 | 0001140361-25-045409 | 1 | published | EDGAR ↗ |
Other insiders at Immunovant, Inc.
- Venker Eric President & Immunovant CEO 94 rows
- Stout Jay S Chief Technology Officer 19 rows
- Gloria Melanie Chief Operating Officer 17 rows
- Pande Atul Director 17 rows
- Torti Frank President and Vant Chair 17 rows
- Van Tuyl Christopher Chief Legal Officer 15 rows
- Fromkin Andrew J. Director 14 rows
- Girao Tiago Chief Financial Officer 7 rows
- Hughes Douglas J. Director 4 rows
- Bauer Jake Director 3 rows
Everyone on file, with contracts and lobbying under the company's name: Immunovant, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | December 12, 2025 | October 5, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.